Kymera Therapeutics (KYMR) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Kymera Therapeutics (KYMR) do?
Kymera Therapeutics Inc (KYMR) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Discovers and tests targeted protein degradation medicines for treating inflammatory diseases and various cancers. Develops targeted protein degrader medicines to eliminate disease-causing proteins that standard drugs cannot block. It is worth $10.19B on the market and sold $102.23M over the last year.
- Market cap
- $10.19B
- P/E ratio
- None (reported a loss)
- Annual sales
- $102.23M
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 18, 2026
KYMR’s flags, in plain English
Each flag is a number from Kymera Therapeutics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.
Stupid Cash
Can pay this year's bills 11.1 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Low debt
Low debt, only 5% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Wide Gross Margin
Gross margin of 92.1% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Burning Cash
Losing money, profit margin of -341.8%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.
1 more green flag and 2 more risk notes open with the free trial. Try it free for 7 days.
Questions about KYMR
How big is Kymera Therapeutics?
Kymera Therapeutics’ market cap is $10.19B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $102.23M: what customers paid the company over the last year, before any costs.
What is KYMR’s P/E ratio?
KYMR has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with KYMR?
The business generates no commercial product sales and relies entirely on collaboration funding and cash reserves to sustain heavy research spending. That is one risk on Kymera Therapeutics’ card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Kymera Therapeutics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. KYMR’s filings on SEC.gov. The Margin Monkey is research, not advice.
